Structural basis for low-affinity binding of non-R2 carboxylate-substituted tricyclic quinoline analogs to CK2α:...

Area of Science:

• Biochemistry and Molecular Biology
• Medicinal Chemistry
• Structural Biology

Background:

• Protein kinase CK2 is a promising target for cancer therapy.
• CX-4945 is a first-in-class CK2 inhibitor in clinical trials for solid tumors.
• Analogs lacking the R2 carboxylate group exhibit drastically reduced potency.

Purpose of the Study:

• To elucidate the structural basis for the reduced potency of CX-4945 analogs lacking the R2 carboxylate.
• To understand how R2 and R3 substituents influence CK2 inhibitor binding affinity.
• To identify allosteric mechanisms affected by these structural modifications.

Main Methods:

• Molecular docking simulations
• Molecular dynamics simulations
• In vitro biochemical assays (implied by potency data)
• Energy calculations and residue-based energy decomposition

Main Results:

• Non-R2 carboxylate analogs showed significantly lower binding affinity compared to CX-4945.
• Structural changes in CK2α and ligand orientation were observed in analogs.
• Inappropriate electrostatic interactions and altered protein-ligand recognition were identified.
• Allosteric modulation involving the G-loop, C-loop, and β4/β5 loop was proposed.

Conclusions:

• The R2 carboxylate group is critical for high-affinity binding of CX-4945 to CK2α.
• Structural and electrostatic factors govern the potency of these CK2 inhibitors.
• Findings provide a rational basis for designing next-generation, more potent CK2 inhibitors for cancer treatment.